Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 452-330-3 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Not reported
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 015
- Report date:
- 2015
Materials and methods
- Objective of study:
- absorption
- distribution
- excretion
- metabolism
- other: Prediction of in vivo exposure in the male and female rat
Test guideline
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- There are currently no specific regulatory guidelines that cover in vitro toxicokinetics. However, this type of work is exemplified in OECD 417 (22nd July 2010) Guideline for the testing of chemicals, Toxicokinetics, Supplemental approaches, use of in vitro information (paragraphs 59-61), and use of toxicokinetic modelling (paragraph 65). The work carried out also meets the spirit of the European Chemical Agency Guidance for the Implementation of REACH. i.e. Guidance on information requirements and chemical safety assessment, chapter R.7C: endpoint specific guidance (ECHA-12-G-23-EN), sections R.7.12.2.2 generating and integrating TK information, in silico methods – kinetic modelling, and Appendix R.7.12-2 prediction of toxicokinetics integrating information generated in silico and in vitro. All experimental work was carried out against appropriate well recognised and established control compounds detailed in the methods and the study data only reported when the control data fell within acceptable predefined limits.
- GLP compliance:
- no
Test material
- Reference substance name:
- -
- EC Number:
- 452-330-3
- EC Name:
- -
- Cas Number:
- 314020-40-1
- Molecular formula:
- C14H20N2O2
- IUPAC Name:
- 2-(2,6-diethyl-4-methyl-phenyl)propanediamide
- Test material form:
- solid: particulate/powder
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- rat
- Strain:
- Wistar
Administration / exposure
- Vehicle:
- DMSO
Results and discussion
Any other information on results incl. tables
MICROSOMAL INTRINSIC CLEARANCE
The in vitro CLint of the test substance in male Wistar rat microsomes was 1.45 ± 3.25 µL/min/mg protein. This was characterised by 9.6% depletion over 45 minutes. The in vitro CLint in female Wistar rat microsomes was 1.79 ± 3.85 µL/min/mg protein, characterised by 9.1% depletion over 45 minutes. In the absence of NADPH, there was approximately 4% depletion over 45 minutes in male microsomes and approximately 4.2% depletion over 45 minutes in female microsomes, indicating no non NADPH dependent metabolism. In the absence of microsomes, there was <1 % loss of the test substance over 45 minutes suggesting no potential chemical instability of the molecule in this matrix.
HEPATOCYTE INTRINSIC CLEARANCE
The in vitro CLint of the test substance in male Wistar rat hepatocytes was 1.54 ± 1.17 µL/min/10^-6 cells characterised by no depletion over 60 minutes. The in vitro CLint in female Wistar rat hepatocytes was 0.182 ± 0.651 µL/min/10^-6 cells characterised by 2.6% depletion over 60 minutes. In the absence of live hepatocytes, there was no loss of CA3250 at the 60 minute time point, suggesting no potential chemical instability of the molecule in this matrix. Due to the negligible intrinsic clearance in hepatocytes it was considered appropriate to use the microsomal data for modelling purposes.
PLASMA PROTEIN BINDING
The fraction of test substance unbound in plasma (fup) was 0.893 ± 0.142 in male plasma and in female plasma was 0.612 ± 0.0452. The recovery of test substance in the incubations was 82.6 and 93.4% respectively.
CACO-2 PERMEABILITY
The apparent permeability (Papp) of test substance across Caco-2 cell monolayers was 25.7 x 10^-6 cms-1 ± 1.86 x 10-6cms -1. The recovery of test substance from the incubation media was 92.9%.
CLOE PK™ - PK SIMULATION
The following parameters were used for Cloe PK™ modelling:
Molecular weight: 248.32
LogP: 1.1
pKa: Neutral
Aqueous solubility at pH 7.96 (g/L): 1.6
Fup: 0.893 for males 0.612 for females
Microsomal CLint (µL/min/mg): 1.45 for males 1.79 for females
Papp (cms-1 ): 25.7 x 10^-6
Certain physiological assumptions were made within the model such as body weight, hepatic blood flow, hepatic mass fraction and microsomal protein content.
TABLE 1: Median predicted pharmacokinetic parameters derived using Cloe PKTM simulating intravenous administration at doses of 15, 150 and 1000 mg/kg in male and female rats
Parameter |
15 mg/kg |
|
150 mg/kg |
|
1000 mg/kg |
|
|
Male |
Female |
Male |
Female |
Male |
Female |
Cmax (µg/mL) |
760 |
870 |
7600 |
8700 |
51000 |
58000 |
AUC (µg.h/mL) |
63 |
81 |
630 |
810 |
4200 |
5400 |
T ½ (h) |
33 |
28 |
33 |
28 |
33 |
28 |
Vd (L/kg) |
11 |
6.8 |
11 |
6.8 |
11 |
6.8 |
Total CL (mL/min/mg) |
4 |
3.1 |
4 |
3.1 |
4 |
3.1 |
MRTinf (h) |
22 |
19 |
22 |
19 |
22 |
19 |
Vss (L/kg) |
5.4 |
3.7 |
5.4 |
3.7 |
5.4 |
3.7 |
Elimination rate (h-1) |
0.021 |
0.024 |
0.021 |
0.024 |
0.021 |
0.024 |
TABLE 2: Median predicted pharmacokinetic parameters derived using Cloe PK™ simulating oral administration at doses of 15, 150 and 1000 mg/kg in male and female rats
Parameter |
15 mg/kg |
|
150 mg/kg |
|
1000 mg/kg |
|
|
Male |
Female |
Male |
Female |
Male |
Female |
Cmax (µg/mL) |
4.2 |
5.8 |
41 |
57 |
140 |
190 |
Tmax (h) |
2.5 |
2.5 |
2.4 |
2.4 |
3.3 |
3.3 |
AUC (µg.h/mL) |
60 |
78 |
590 |
780 |
2500 |
3200 |
T ½ (h) |
34 |
29 |
33 |
29 |
36 |
31 |
Vd (L/kg) |
11 |
6.9 |
11 |
6.9 |
12 |
7.5 |
Elimination rate (h-1) |
0.021 |
0.024 |
0.021 |
0.024 |
0.019 |
0.023 |
Bioavailability (%) |
0.93 |
0.94 |
0.93 |
0.93 |
0.57 |
0.57 |
Fraction absorbed |
1 |
1 |
0.99 |
0.99 |
0.61 |
0.61 |
Applicant's summary and conclusion
- Conclusions:
- Based upon an in vitro to in vivo extrapolation utilising recognised, established and validated in vitro systems carried out by Cyprotex Discovery Ltd. together with their commercially accepted physiologically based pharmacokinetic model (Cloe PK™), the test substance, when administered in vivo to male and female rats, is predicted to have a good fraction absorbed across the gastrointestinal tract following doses of 15, 150 or 1000 mg/kg (approx. 99% at lower doses reducing to 61% at 1000 mg/kg). This translates to a systemic oral bioavailability of 57-100% in male and female rats over this dose range. In general in vivo the test substance would be expected to be a low clearance compound that distributes widely into tissues with a mean residence time in the body of around 19-22 hours.
- Executive summary:
This study was designed to assess the in vivo pharmacokinetic behaviour of the test substance via an in vitro to in vivo extrapolation (IVIVE) to help put into context the findings of toxicology studies carried out separately to this report. In vitro metabolic stability, plasma protein binding and Caco-2 permeability were determined by Cyprotex Discovery Ltd., Macclesfield, UK and the data used in the physiologically based pharmacokinetic (PBPK) model, Cloe PKTM, to simulate the predicted in vivo exposure in male and female rat at 100, 300 and 1000 mg/kg. Physical chemistry data including solubility, logP and pKa was provided by Syngenta for the purposes of modelling and simulation.
The in vitro CLint of the test substance in male Wistar rat microsomes was 1.45 ± 3.25 µL/min/mg protein. This was characterised by 9.6% depletion over 45 minutes. The in vitro CLint in female Wistar rat microsomes was 1.79 ± 3.85 µL/min/mg protein characterised by 9.1% depletion over 45 minutes. The in vitro CLint of the test substance in male Wistar rat hepatocytes was 1.54 ± 1.17 µL/min/10^-6 cells characterised by no depletion over 60 minutes. The in vitro CLint in female Wistar rat hepatocytes was 0.182 ± 0.651 µL/min/10-6 cells characterised by 2.6% depletion over 60 minutes. Due to the negligible intrinsic clearance in hepatocytes it was considered appropriate to use the microsomal data for modelling purposes. The fraction of test substance unbound in plasma (fup) was 0.893 ± 0.142 in male plasma and in female plasma was 0.612 ± 0.0452. The recovery of test substance in the incubations was 82.6 and 93.4%, respectively. The apparent permeability (Papp) of test substance across Caco-2 cell monolayers was 25.7 x 10^-6 cms^-1 ± 1.86 x 10-6cms^-1. The recovery of test substance from the incubation media was 92.9%. The predicted median pharmacokinetic parameters for the test substance using Cloe PKTM simulating oral administration at doses of 15, 150 and 1000 mg/kg in male and female rats is summarised below.
Parameter
15 mg/kg
150 mg/kg
1000 mg/kg
Male
Female
Male
Female
Male
Female
Cmax (µg/mL)
4.2
5.8
41
57
140
190
Tmax (h)
2.5
2.5
2.4
2.4
3.3
3.3
AUC (µg.h/mL)
60
78
590
780
2500
3200
T ½ (h)
33
28
33
28
33
28
Vd (L/kg)
11
6.8
11
6.8
11
6.8
CL (mL/min/kg)
4
3.1
4
3.1
4
3.1
MRTinf (h)
22
19
22
19
22
19
Vss (L/kg)
5.4
3.7
5.4
3.7
5.4
3.7
Bioavailability (%)
0.93
0.94
0.93
0.93
0.57
0.57
Fraction absorbed
1
1
0.99
0.99
0.61
0.61
Based upon an in vitro to in vivo extrapolation utilising recognised, established and validated in vitro systems carried out by Cyprotex Discovery Ltd. together with their commercially accepted physiologically based pharmacokinetic model (Cloe PK™), the test substance, when administered in vivo to male and female rats, is predicted to have a good fraction absorbed across the gastrointestinal tract following doses of 15, 150 or 1000 mg/kg (approx. 99% at lower doses reducing to 61% at 1000 mg/kg). This translates to a systemic oral bioavailability of 57-100% in male and female rats over this dose range. In general in vivo the test substance would be expected to be a low clearance compound that distributes widely into tissues with a mean residence time in the body of around 19-22 hours.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.